The evolution of molecular diagnosis using digital polymerase chain reaction (dPCR) to detect cancer via cell-free DNA (cfDNA) and circulating tumor cells (CTC).
Cancer is one of the most causes of death worldwide. The onset of cancer may be initiated due to a variety of factors such as environmental, genetically or even due to personal lifestyle choices. To counteract this tremendous increase, the demand for new technology rises. In this way, the use of digital polymerase chain reaction (dPCR) shows to be a promising methodology in the early detection of many types of cancers. Furthermore, several researchers confirmed that the use of tumor cell-free DNA (cfDNA) and circulating tumor cells (CTC) in peripheral blood is essential in revealing an early prognosis of such disease. Beside this, it was established that dPCR might be used in a much more efficient, accurate and reliable manner to amplify a variety of genetic material up to the identification of mutations in hematological diseases. Therefore, this article demonstrates the differences between conventional PCR and dPCR as a molecular technique to detect early onset of cancer. Furthermore, CTC and cfDNA were official approved by the Food and Drug Administration (FDA) as new biological biomarker in cancer development and monitoring. This article is protected by copyright. All rights reserved.